« 100 millions de vies en bonne santé » : comment l'Égypte a dépisté toute une nation, et pourquoi le dépistage de masse compte

In the autumn of 2018, Egypt launched one of the largest public health screening campaigns ever attempted anywhere: '100 Million Healthy Lives'. The goal was audacious — to offer every adult in the country a free test for hepatitis C along with checks for the main chronic disease risks: high blood pressure, elevated blood sugar, and obesity. Within months, tens of millions of people had passed through the screening points. The campaign changed Egypt's health map and became a case study discussed around the world.

To understand why hepatitis C stood at the campaign's centre, one must go back decades. For years, Egypt recorded the highest prevalence of hepatitis C in the world. Much of the epidemic traces to mass campaigns in the mid-twentieth century that treated schistosomiasis — a parasitic disease of the Nile valley — with injections, at a time when needles were reused and sterilisation was inadequate. The virus spread silently through a generation, and because hepatitis C can damage the liver for twenty years without symptoms, most carriers had no idea they were infected.

What made a national campaign possible was a revolution in treatment. Direct-acting antiviral drugs, introduced in the 2010s, cure well over ninety per cent of hepatitis C cases with a short course of pills — a dramatic change from the old interferon injections, which were long, harsh, and often unsuccessful. Egypt negotiated sharply reduced prices and licensed local production of affordable generic versions, driving the cost of a cure down to a small fraction of international prices. Cheap cure created a new logic: if treatment is available, the priority becomes finding the silent carriers.

The screening itself was designed for speed and reach. Teams set up points in health units and hospitals, but also in youth centres, railway stations, mosques, churches, and workplaces. A visit took minutes: a rapid finger-prick antibody test for hepatitis C, a blood-pressure reading, a blood-sugar check, and height and weight to calculate body mass index. Results were registered electronically against the national ID number, and everything was free. Removing every barrier — cost, distance, paperwork — was the point; mass screening only works when taking the test is easier than avoiding it.

Screening alone cures no one, and the campaign's real strength was what happened next. Anyone whose rapid test suggested hepatitis C was referred for a confirmatory PCR test, then for medical evaluation, then — if the infection was active — for a free course of antiviral treatment. Those found with high blood pressure or elevated blood sugar were directed into follow-up care for chronic disease. This chain from test to treatment is what public health specialists call 'linkage to care', and it is the difference between a statistics exercise and a health intervention.

The results were substantial. Tens of millions of adults were screened in the campaign's main phases, hundreds of thousands of infections were confirmed and treated, and the measured prevalence of hepatitis C in Egypt fell steeply compared with the levels recorded a decade earlier. In October 2023, the World Health Organization announced that Egypt had become the first country to achieve 'gold tier' status on the path to eliminating hepatitis C — formal recognition that the country had met demanding criteria for diagnosis and treatment coverage.

Why does mass screening matter so much? Because the deadliest chronic diseases are silent in their early years. Hepatitis C destroys the liver quietly; high blood pressure damages arteries, heart, and kidneys for a decade before the first crisis; type 2 diabetes can circulate unnoticed while it harms the eyes and nerves. By the time symptoms force a person to a doctor, the damage is often advanced and the treatment far more expensive. Screening flips this timeline: it finds disease when it is cheapest and easiest to treat.

The campaign also built infrastructure that outlived it. Follow-on presidential health initiatives used the same model for other conditions: screening women for breast cancer and reproductive health risks, checking schoolchildren for anaemia, obesity, and stunting, monitoring the health of mothers and newborns, and screening for kidney disease and other chronic conditions. Each initiative reuses the same logic — bring free, quick testing to where people already are, register the results digitally, and connect every positive case to care.

For health policymakers, the Egyptian experience carries clear lessons. First, an ambitious campaign needs three legs: political commitment at the highest level, cheap and rapid diagnostics, and guaranteed affordable treatment for those who test positive — remove any leg and the model collapses. Second, going to people where they live beats waiting for them in clinics. Third, the data generated by mass screening is itself a public asset, giving planners a real map of disease burden instead of estimates.

For the individual citizen, the lesson is simpler and more personal. A blood-pressure reading takes one minute; a blood-sugar test takes a few more; both can reveal a threat years before it becomes a crisis. The campaign's deepest legacy would be a culture in which Egyptians check these numbers periodically — at a pharmacy, a health unit, or a doctor's visit — without waiting for a national campaign to knock on the door. Screening once made history; screening regularly makes health.